Article Figures & Data
Figures
- FIGURE 1.
(A) Schematic representation of BIP-RIT approach, showing mean activity per whole mouse body at different time points after BIP-RIT (50 MBq) and IP-RIT (10 MBq) with 177Lu-16F12 (n = 7 mice/group). (B and C) Merged whole-body SPECT/CT images of mice bearing AN3CA endometrial carcinoma cell tumor xenografts at 24 h after BIP-RIT (B) or IP-RIT (C).
- FIGURE 2.
Therapeutic efficacy of 177Lu-16F12 (A and B) and 213Bi-16F12 (C and D) after IP-RIT (A and C) and BIP-RIT (B and D). Tumor mass (mean ± SD) was calculated at days 10, 20, and 30 after treatment. *P < 0.05 between therapeutic group and NaCl controls, between 213Bi-16F12 and 177Lu-16F12, or between IP-RIT and BIP-RIT (n = 7 mice per group).
- FIGURE 3.
Tissue distribution of 177Lu-16F12 (A and B) and 213Bi-16F12 (C and D). Data are mean (±SD) %IA/g after IP-RIT (A and C) or %RA/g after BIP-RIT (B and D) (n = 4 mice/group).
- FIGURE 4.
Time–activity curves (not corrected for decay) for blood (A) and AN3CA endometrial carcinoma cell tumor xenografts (B) measured with 177Lu-16F12 and for blood (C) and tumor (D) measured with 213Bi-16F12. Fitting of distribution (with 95% confidence intervals) using mono- or biexponential components is shown on A–C but, for sake of clarify, not on D.
- FIGURE 5.
Incorporated therapeutic 177Lu-16F12 activity over time for tumors (A), blood (B), liver (C), and kidneys (D) after IP-RIT or BIP-RIT, with mean absorbed dose shown in key.
- FIGURE 6.
Incorporated therapeutic 213Bi-16F12 activity over time for tumors (A), blood (B), liver (C), and kidneys (D) after IP-RIT or BIP-RIT, with mean absorbed dose shown in key.
- FIGURE 7.
(A) Hematologic toxicity. White blood cell count, hemoglobin level, and weight were monitored in healthy mice at various times from days 0 to 36 after IP-RIT and BIP-RIT with 177Lu-16F12 or 213Bi-16F12 and expressed as ratio relative to treatment with NaCl control. (B) Whole-body PET/CT images of mice bearing subcutaneous AN3CA cell tumor xenografts in right flank at 24, 48, 72, and 96 h after injection of 89Zr-16F12C.
Tables
IP-RIT BIP-RIT Site Absorbed dose (Gy/MBq)* Absorbed dose, therapy (Gy) Absorbed dose (Gy/MBq)* Absorbed dose, therapy (Gy) Blood 1.347 ± 0.305 13.5 ± 3.0 0.086 ± 0.042 4.3 ± 2.1 Tumor 0.560 ± 0.190 5.6 ± 2.1 0.050 ± 0.016 2.5 ± 1.0 Liver 0.973 ± 0.244 9.7 ± 2.4 0.054 ± 0.030 2.7 ± 1.5 Kidneys 0.717 ± 0.171 7.2 ± 1.7 0.066 ± 0.027 3.3 ± 1.3 Lungs 0.461 ± 0.158 4.6 ± 1.6 0.031 ± 0.021 1.5 ± 1.1 Spleen 0.899 ± 0.359 9.0 ± 3.6 0.045 ± 0.031 2.2 ± 1.5 Heart 0.388 ± 0.108 3.9 ± 1.1 0.024 ± 0.018 1.2 ± 0.9 Bones 0.183 ± 0.063 1.8 ± 0.6 0.014 ± 0.008 0.7 ± 0.4 Stomach 0.170 ± 0.021 1.7 ± 0.2 0.011 ± 0.004 0.6 ± 0.2 Small intestine 0.178 ± 0.045 1.8 ± 0.4 0.008 ± 0.003 0.4 ± 0.1 Large intestine 0.056 ± 0.015 0.6 ± 0.1 0.004 ± 0.003 0.2 ± 0.1 Carcass 0.248 ± 0.094 2.5 ± 0.9 0.016 ± 0.007 0.8 ± 0.3 Bone marrow 0.456 ± 0.122 4.6 ± 1.2 0.029 ± 0.017 1.5 ± 0.8 ↵* Corresponds to absorbed dose per unit of injected activity (MBq) during therapy.
Data are mean ± SD.
IP-RIT BIP-RIT Site Absorbed dose (Gy/MBq)* Absorbed dose, therapy (Gy) Absorbed dose (Gy/MBq)* Absorbed dose, therapy (Gy) Blood 0.126 ± 0.029 1.63 ± 0.37 0.013 ± 0.010 0.49 ± 0.37 Tumor 0.169 ± 0.227 2.18 ± 2.95 0.081 ± 0.081 3.00 ± 2.98 Liver 0.042 ± 0.011 0.55 ± 0.15 0.004 ± 0.003 0.17 ± 0.10 Kidneys 0.106 ± 0.015 1.37 ± 0.20 0.010 ± 0.013 0.38 ± 0.47 Lungs 0.043 ± 0.017 0.55 ± 0.22 0.004 ± 0.002 0.16 ± 0.09 Spleen 0.046 ± 0.023 0.60 ± 0.30 0.008 ± 0.010 0.30 ± 0.36 Heart 0.038 ± 0.019 0.49 ± 0.25 0.003 ± 0.002 0.12 ± 0.07 Bones 0.013 ± 0.008 0.17 ± 0.10 0.002 ± 0.003 0.08 ± 0.10 Stomach 0.047 ± 0.029 0.61 ± 0.37 0.006 ± 0.007 0.24 ± 0.24 Small intestine 0.045 ± 0.009 0.59 ± 0.11 0.004 ± 0.003 0.15 ± 0.10 Large intestine 0.028 ± 0.015 0.37 ± 0.19 0.003 ± 0.003 0.10 ± 0.11 Carcass 0.033 ± 0.031 0.42 ± 0.40 0.005 ± 0.009 0.20 ± 0.33 Bone marrow 0.050 ± 0.012 0.65 ± 0.15 0.005 ± 0.004 0.20 ± 0.15 ↵* Corresponds to absorbed dose per unit of injected activity (MBq) during therapy.
Data are mean ± SD.
